Experienced in Porphyria

Dr. Clarence S. Adoo

Hematology Oncology | Hematology | Oncology
Honorhealth Ambulatory
10320 W Mcdowell Rd, Suite 9030, 
Avondale, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Porphyria
Honorhealth Ambulatory
10320 W Mcdowell Rd, Suite 9030, 
Avondale, AZ 
OverviewInsuranceLocationsClinical Research

Overview

Clarence Adoo is a Hematologist Oncology specialist and a Hematologist in Avondale, Arizona. Dr. Adoo and is rated as an Experienced provider by MediFind in the treatment of Porphyria. His top areas of expertise are Breast Cancer, Multiple Myeloma, Paget Disease of the Breast, and Childhood Iron Deficiency Anemia. Dr. Adoo is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Banner Boswell Medical Center
Honor Health John C. Lincoln Medical Center
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  UnitedHealthcare
  •  Oscar
  •  Humana

Locations

HONORHEALTH AMBULATORY
10320 W Mcdowell Rd, Suite 9030, Avondale, AZ 85392
Other Locations
HONORHEALTH AMBULATORY
5750 W Thunderbird Rd, Suite C300, Glendale, AZ 85306
HONORHEALTH AMBULATORY
10510 N 92nd St, Scottsdale, AZ 85258

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or TNBC Failing Front-line Chemotherapy for Metastatic Disease
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or TNBC Failing Front-line Chemotherapy for Metastatic Disease
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Biological, Drug
Study Drugs: Imprime PGG, Pembrolizumab
Study Phase: Phase 2
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: December 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

1 Total Publications

An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
Journal: Cancer medicine
Published: October 20, 2017
Similar Doctors
Distinguished in Porphyria
Dr. Danielle Nance
Hematology | Neuroradiology
Distinguished in Porphyria
Dr. Danielle Nance
Hematology | Neuroradiology

Banner Cancer Center Specialists LLC

2946 E Banner Gateway Dr, 
Gilbert, AZ 
 (32.6 mi)
480-256-6444
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Danielle Nance is a Hematologist and a Neuroradiologist in Gilbert, Arizona. Dr. Nance and is rated as a Distinguished provider by MediFind in the treatment of Porphyria. Her top areas of expertise are Acute Hepatic Porphyria (AHP), Porphyria, Von Willebrand Disease (VWD), and Heyde Syndrome. Dr. Nance is currently accepting new patients.

Advanced in Porphyria
Dr. Robin L. Obenchain
Hematology Oncology | Oncology
Advanced in Porphyria
Dr. Robin L. Obenchain
Hematology Oncology | Oncology

Honorhealth Ambulatory

1110 S Dobson Rd, Suite 1, 
Chandler, AZ 
 (26.4 mi)
855-485-4673
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Robin Obenchain is a Hematologist Oncology specialist and an Oncologist in Chandler, Arizona. Dr. Obenchain and is rated as a Distinguished provider by MediFind in the treatment of Porphyria. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Obenchain is currently accepting new patients.

Advanced in Porphyria
Dr. Fade A. Mahmoud
Oncology | Hospital Medicine | Hematology Oncology
Advanced in Porphyria
Dr. Fade A. Mahmoud
Oncology | Hospital Medicine | Hematology Oncology

Banner Cancer Center Specialists LLC

2946 E Banner Gateway Dr, 
Gilbert, AZ 
 (32.6 mi)
480-256-6444
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Fade Mahmoud is an Oncologist and a Hospital Medicine provider in Gilbert, Arizona. Dr. Mahmoud and is rated as a Distinguished provider by MediFind in the treatment of Porphyria. His top areas of expertise are Melanoma, Bone Tumor, Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, and Orchiectomy. Dr. Mahmoud is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile